foxo4 dri senolytic peptide human trial 2024 FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells FOXO4-DRI: Status, Cancer – 2026 FDA Peptide Reclassification Size:Gallon Pica
Pay in 4 interest-free payments of $6.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16